Literature DB >> 7634382

Effects of sodium thiosulfate on the pharmacokinetics of unchanged cisplatin and on the distribution of platinum species in rat kidney: protective mechanism against cisplatin nephrotoxicity.

N Nagai1, K Hotta, H Yamamura, H Ogata.   

Abstract

To investigate the mechanism underlying the protective effect against cisplatin (CDDP) nephrotoxicity of its antidote, sodium thiosulfate (STS), the effects of STS on the pharmacokinetics of unchanged CDDP and on the distribution of unchanged CDDP and high and low molecular mass metabolites (fixed and mobile metabolites) in the kidney 1 min after a bolus injection of CDDP (5 mg/kg) to rats were studied. A decrease in the plasma concentration of unchanged CDDP and an increase in the plasma concentration of mobile metabolites were observed in the rats after the bolus injection of CDDP in combination with STS infusion for 30 min (1200 mg/kg). Although STS accelerated platinum excretion during the first 10 min after CDDP injection, unchanged CDDP was not excreted in the urine in the STS-treated rats. Total kidney platinum 1 min after the bolus injection of CDDP was detected mainly as unchanged CDDP (86% of the total platinum) in the rats given CDDP alone. However, in the STS-treated rats, the total kidney platinum was decreased to 62% of the level in the rats given CDDP alone, and the platinum species detected in the kidney were mainly mobile metabolites. Only 24% of the total kidney platinum was detected as unchanged CDDP in the STS-treated rats. The loss of body weight and increases in BUN and serum creatinine levels usually observed after a bolus injection of CDDP were completely prevented by STS coadministration. The present study provides information about unchanged CDDP pharmacokinetics and the distribution of unchanged CDDP and some of its generic metabolites in the kidney when STS is coadministered as an antidote. These results show that the protective effect of STS against CDDP nephrotoxicity can be attributed to the formation of inactive mobile metabolites by a direct reaction between unchanged CDDP and STS in the systemic circulation, resulting in a reduction in the amount of unchanged CDDP in the kidney.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7634382     DOI: 10.1007/BF00686189

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  29 in total

1.  Interaction of cisplatin and carboplatin with sodium thiosulfate: reaction rates and protein binding.

Authors:  F Elferink; W J van der Vijgh; I Klein; H M Pinedo
Journal:  Clin Chem       Date:  1986-04       Impact factor: 8.327

2.  Quantitative determination of unchanged cisplatin in rat kidney and liver by high-performance liquid chromatography.

Authors:  K Hanada; N Nagai; H Ogata
Journal:  J Chromatogr B Biomed Appl       Date:  1995-01-06

3.  "Two-route chemotherapy" using cis-diamminedichloroplatinum(II) and its antidote, sodium thiosulfate, combined with angiotensin II is effective against peritoneally disseminated cancer in rats.

Authors:  H Kobayashi; K Hasuda; K Aoki; T Kuroiwa; S Taniguchi; T Baba
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

4.  The effect of sodium thiosulfate on subcellular localization of platinum in rat kidney after treatment with cisplatin.

Authors:  J Uozumi; C L Litterst
Journal:  Cancer Lett       Date:  1986-09       Impact factor: 8.679

5.  Disposition of unchanged cisplatin in patients with ovarian cancer.

Authors:  P A Reece; I Stafford; M Davy; S Freeman
Journal:  Clin Pharmacol Ther       Date:  1987-09       Impact factor: 6.875

6.  Effect of sodium thiosulfate on cis-dichlorodiammineplatinum(II) toxicity and antitumor activity in L1210 leukemia.

Authors:  S B Howell; R Taetle
Journal:  Cancer Treat Rep       Date:  1980 Apr-May

7.  Efficacy of two-route chemotherapy using cis-diamminedichloroplatinum(II) and its antidote, sodium thiosulfate, in combination with angiotensin II in a rat limb tumor.

Authors:  T Kuroiwa; K Aoki; S Taniguchi; K Hasuda; T Baba
Journal:  Cancer Res       Date:  1987-07-15       Impact factor: 12.701

8.  Inactivation of cis-diamminedichloroplatinum (II) in blood and protection of its toxicity by sodium thiosulfate in rabbits.

Authors:  Y Iwamoto; T Kawano; M Ishizawa; K Aoki; T Kuroiwa; T Baba
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

9.  "Two-route chemotherapy" using high-dose ip cisplatin and iv sodium thiosulfate, its antidote, for peritoneally disseminated cancer in mice.

Authors:  Y Iwamoto; T Kawano; J Uozumi; K Aoki; T Baba
Journal:  Cancer Treat Rep       Date:  1984-11

10.  Intraperitoneal cis-diamminedichloroplatinum with systemic thiosulfate protection.

Authors:  S B Howell; C E Pfeifle; W E Wung; R A Olshen
Journal:  Cancer Res       Date:  1983-03       Impact factor: 12.701

View more
  8 in total

1.  Impact of superselective transarterial infusion therapy of high-dose cisplatin on maxillary cancer with orbital invasion.

Authors:  M Kanoto; A Oda; T Hosoya; K Nemoto; A Ishida; T Nasu; S Koike; M Aoyagi
Journal:  AJNR Am J Neuroradiol       Date:  2010-04-01       Impact factor: 3.825

Review 2.  Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy.

Authors:  M Links; C Lewis
Journal:  Drugs       Date:  1999-03       Impact factor: 9.546

3.  Effects of disopyramide and verapamil on renal disposition and nephrotoxicity of cisplatin in rats.

Authors:  K Hanada; K Odaka; A Kudo; H Ogata
Journal:  Pharm Res       Date:  1999-10       Impact factor: 4.200

4.  Sodium thiosulfate during cisplatin-based hyperthermic intraperitoneal chemotherapy is associated with transient hypernatraemia without clinical sequelae.

Authors:  Anais Alonso; Winston Liauw; Helen Kennedy; Nayef A Alzahrani; David L Morris
Journal:  Pleura Peritoneum       Date:  2022-05-02

Review 5.  Cisplatin overdose: toxicities and management.

Authors:  Roger Y Tsang; Turki Al-Fayea; Heather-Jane Au
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

Review 6.  Tuning the metabolism of the anticancer drug cisplatin with chemoprotective agents to improve its safety and efficacy.

Authors:  Melani Sooriyaarachchi; Graham N George; Ingrid J Pickering; Aru Narendran; Jürgen Gailer
Journal:  Metallomics       Date:  2016-11-09       Impact factor: 4.526

Review 7.  Cisplatin-Induced Nephrotoxicity; Protective Supplements and Gender Differences

Authors:  Mehdi Nematbakhsh; Zahra Pezeshki; Fatemeh Eshraghi Jazi; Bahar Mazaheri; Maryam Moeini; Tahereh Safari; Fariba Azarkish; Fatemeh Moslemi; Maryam Maleki; Alireza Rezaei; Shadan Saberi; Aghdas Dehghani; Maryam Malek; Azam Mansouri; Marzieh Ghasemi; Farzaneh Zeinali; Zohreh Zamani; Mitra Navidi; Sima Jilanchi; Soheyla Shirdavani; Farzaneh Ashrafi
Journal:  Asian Pac J Cancer Prev       Date:  2017-02-01

8.  The addition of sodium thiosulphate to hyperthermic intraperitoneal chemotherapy with cisplatin in ovarian cancer.

Authors:  Kate Glennon; Karen Mulligan; Kirsten Carpenter; Ruth Mooney; Jurgen Mulsow; Orla McCormack; William Boyd; Tom Walsh; Ruaidhri McVey; Claire Thompson; Brid Ryan; Katie Padfield; Patrick Murray; Donal J Brennan
Journal:  Gynecol Oncol Rep       Date:  2021-05-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.